The rationale
The 2020 course of the Ettore Majorana Center International School of Molecular Oncology,
directed by Franco Maria Buonaguro, titled BioMedical studies in the Age of Pandemics: the COVID-19 impact on Science (held on line on October 12–15, 2020) was focused on the COVID pandemic and gathered the world leader on the topic.
As of 20 September 2020 SARS-CoV2-19 has infected more than 30 million of people worldwide, carrying an overall mortality of approximately 3.1%, compared with a mortality rate of less than 1% of the influenza. Italy (especially Northern Italy) and several European countries have been badly hit by the epidemic in the March-April period, with a mortality rate > 10%. At the moment the epidemic is prevalently involving United States, Latin America (i.e. Brazil) and Eastern European countries (including the Russian Federation). An effective antiviral treatment is not available. More research and studies are needed in order to develop specific therapeutic and preventive strategies.directed by Franco Maria Buonaguro, titled BioMedical studies in the Age of Pandemics: the COVID-19 impact on Science (held on line on October 12–15, 2020) was focused on the COVID pandemic and gathered the world leader on the topic.
The course is providing an update on most of the open questions on the SARS-CoV-2 infection and the related COVID disease with the contribution of international leading scientists, covering epidemiological, virologic and immunologic aspects, molecular biology issues, therapeutic approaches and preventive strategies, including vaccines.
The course is aimed at doctors and scientists who fight against this deadly pandemic with the most advanced technology.
Unit 1
SARS-COV-2
Virology – Epidemiology - Pathogenesis
VIROLOGY
01 SARS-CoV-2 evolution
01 SARS-CoV-2 evolution
- Massimo Ciccozzi PhD, University Rome (30:27)
02 SARS-CoV-2 immunogenic epitope mapping
- Pasquale Vito PhD, University del Sannio (BN) Italy (19:04)
EPIDEMIOLOGY
03 SARS-CoV-2 Global Pandemic
- Ranieri Guerra, MD WHO – Geneva (21:48)
04 SARS-CoV-2 Italian Pandemic
- Patrizio Pezzotti, MD ISS – Rome (22.32)
05 Environmental surveillance of CoV-2 in Italy
- Giuseppina La Rosa ISS - Rome (17:49)
PATHOGENEIS
06 Antibody role in SARS-CoV-2
- Jinghe Huang, PhD, Fudan Univ. Shanghai -China (25:32)
07 Innate immunity in SARS-CoV-2
- Marisa Gariglio, MD/PhD, Univ EastPiedmont, Novara (23:11)
08 COVID-19 a veterinary perspective
- Alessio Lorusso – IZS Teramo, Italy (16:45)
09 COVID-19 and cytokines
- Adriana Albini, MD Multimedica – Milan (24:48)
Unit 2
SARS-COV-2
COVID-19 Clinical Aspects and Therapeutic Strategies
CLINICAL ASPECTS
01 COVID-19 The impact of the pandemic in Northern Italy and the Health care initial response
- Andrea Giacomelli, MD, Ospedale Sacco-FBF- Milan (22:43)
02 COVID-19 Clinical outcome in solid organ transplant recipients
- Paolo Antonio Grossi, MD – University of Insubria (20:11)
03 Surgical Oncology of the Head & Neck district during COVID-19 pandemic
- Ionna, Salzano, Maglitto – INT-Pascale, Naples, Italy (15:28)
04 Management of oral surgery/dental outpatient procedures during COVID-19 pandemic
- Agostino Guida – INT-Pascale, Naples, Italy (15:36)
ANTI-COVID-19 THERAPEUTIC STRATEGIES-I
05 SARS-CoV-2 anti-virals
- Gui-Qiang Wang MD, Peking University First Hospital (29:32)
06 SARS-CoV-2 treatment in Campania Region
- Alessandro Perrella MD, Campania COVID pandemic Unit (23:04)
07 COVID-19 anti-IL6 treatments
- Paolo Ascierto, MD, INT - Naples (18:43)
08 COVID-19 anti- IL1 &Cytokines treatments
- Giulio Cavalli, MD San Raffaele – Milan (19:19)
ANTI-COVID-19 THERAPEUTIC STRATEGIES-II
09 COVID-19 pandemic treatment and preventive strategies.
- Robert C. Gallo MD, Institute of Human Virology, Baltimore USA (41:00)
10 SARS-CoV-2 anti-polymerase drugs
- Luigi Buonaguro MD, INT-Pascale, Naples, Italy (20:40)
Unit 3
SARS-COV-2
COVID-19 Immunoresponse – Immunotherapy – Vaccines
IMMUNORESPONSE & IMMUNOTHERAPY
01 Humoral immune response in COVID-19
- Gabriel Siracusano, San Raffaele, Milan, Italy (23:51)
02 SARS-CoV-2 plasma treatment
- Raimundo Gazitua MD, Institute Oncologic Chile (13:18)
SPECIFIC ACTIVE VACCINES
03 SARS-CoV-2 vaccines (viral vectors & adeno)
- Stefania Di Marco, IRBM-Advent, Pomezia, Italy (25:41)
04 SARS-CoV-2 genetic vaccination: experiencing a change of paradigm
- Luigi Aurisicchio PhD, Takis, Pomezia Italy (29:57)
NON-SPECIFIC EFFECT OF VACCINES
05 The OVP effect on other diseases
- Konstantin Chumakov, FDA, USA (23:26)
06 Alive vaccine protective effects on other disease: the innate immunity training
- Christine Stabell Benn, MD, Univ of Souther Denmark, DK (19:51)
COVID-related complementary issues
07 COVID-19 Mental health issues
- Felice Iasevoli – Elisabetta F Buonaguro Univ Federico II Naples, Italy (37:06)
08 COVID-19 India’s Health Issues
- Trupti & Ishwar Gilada Univ of Mumbai, India (42:49)
09 COVID-19 global economic impact
- Tatsuo Masuda – Tokyo, Japan (14:26)
10 COVID-19 catastrophic risk assessment
- Sally Leivesley – London, UK (09:34)